Partnership Targets Intraocular Biologics
BioMed X and Boehringer launch new eye therapy research team
-
1
BioMed X and Boehringer Ingelheim have launched a new research team focused on next-generation eye therapies at Boehringer's Ridgefield headquarters.
-
2
The new team, Team NIB, aims to develop a human organotypic in vitro platform for intraocular biologics.
-
3
Dr. Deniz Ugurlu Cimen will lead the team, specializing in stem cell-based disease modeling and advanced 3D human model systems.
-
4
The initiative seeks to create predictive models for drug discovery in eye health, addressing vision-threatening diseases.
-
5
The collaboration combines Boehringer's biologics expertise with BioMed X's innovation model to enhance drug discovery approaches.
